Biomedical subjects
S Ozsoylu
Publications and source records attributed to S Ozsoylu.
High dose intravenous methylprednisolone for Kassabach-Merritt syndrome.
Kassabach-Merritt syndrome involving the sternum in a 2-month-old child is described. Treatment with high dose intravenous methylprednisolone resulted in normalization of the platelet count and disappearance of haemangioma.
Ascites related to cytomegalovirus infection.
Explore the source record for details and available documents.
High-dose intravenous methylprednisolone therapy for anemia associated with diaphyseal dysplasia.
Explore the source record for details and available documents.
Maternal hyperparathyroidism and neonatal rickets.
Explore the source record for details and available documents.
Vitamin D-deficiency rickets and myelofibrosis.
This study was aimed at detecting the early appearance of myelofibrosis by bone marrow biopsy examination in children with vitamin D-deficiency rickets. Twelve children, aged 4 to 18 months, were evaluated. Only a minimal increase of the reticulin was shown in rachitic children without anemia in whom no other laboratory evidence of myelofibrosis was present. Early signs of myelofibrosis with increase of reticulin were present in rachitic infants with anemia. In patients of the same age with iron deficiency anemia, the bone marrow reticulin findings were normal. Bone marrow biopsy after successful treatment of rickets could be repeated in one patient with myelofibrosis; results indicated that the myelofibrosis with anemia associated with vitamin D-deficiency rickets is reversible by vitamin D treatment.
High dose intravenous methylprednisolone for acquired aplastic anaemia, Diamond-Blackfan syndrome and aregenerative anaemias.
Explore the source record for details and available documents.
High-dose intravenous methylprednisolone for acute childhood idiopathic thrombocytopenic purpura.
49 children with acute idiopathic thrombocytopenic purpura (ITP) were divided into non-treatment, oral prednisone (2 mg/kg), and high-dose intravenous methylprednisolone (HIVMP) treatment groups which consisted of 17, 16 and 16 children respectively. Platelet counts rose above 150,000/microliters over a 2-week period in 5 (29.4%) children in the first group, 5 (31.2%) in the second group and 15 (93.7%) children in the third group. Platelet counts reached the normal level in only 3 days in 11 (68.7%) children treated with HIVMP. Initially, antiplatelet antibodies (APA) were shown by the Handin and Stossel method in every patient. With normalization of platelet counts, the antibodies decreased but could still be detected in every case; antibody decrease was greater in the HIVMP group. With the exception of mild cushingoid appearance, none of the major corticosteroid side effects was observed in the treated children.
High-dose methylprednisolone for remission induction in children with acute nonlymphoblastic leukemia.
The effectiveness of high-dose intravenous methylprednisolone (HIVMP) in inducing an initial remission was examined in a child with acute nonlymphoblastic leukemia (ANLL). Dramatic clinical and hematological improvement with 7% marrow blasts was obtained in 3 weeks with HIVMP treatment without giving any other antileukemic drugs. Based on the results of this preliminary observation we suggest that high-dose methylprednisolone (20-30 mg/kg) might be a useful approach when applied as an initial short treatment in childhood ANLL.
About leukocyte alkaline phosphatase.
Explore the source record for details and available documents.
Intravenous methylprednisolone for myelofibrosis.
Explore the source record for details and available documents.
High dose intravenous methylprednisolone for chronic idiopathic thrombocytopenic purpura.
Explore the source record for details and available documents.
Erythroblastopenic crisis in iron deficiency anemia.
Explore the source record for details and available documents.
Corticosteroid and factor VIII.
Explore the source record for details and available documents.
Hemoglobin C-beta (0) thalassemia.
Explore the source record for details and available documents.
High-dose methylprednisolone for acute nonlymphoblastic leukemia.
Explore the source record for details and available documents.
High-dose intravenous methylprednisolone for immune thrombocytopenic purpura.
Explore the source record for details and available documents.
High-dose intravenous methylprednisolone for idiopathic myelofibrosis.
Explore the source record for details and available documents.